Sandoz Scientific Standalone Event in Russia “Combat Infections to Save Lives”

  • Sandoz Scientific Standalone Event “Combat Infections to Save Lives” aims at increasing access to information in the field of antibiotic therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • First event in the field of anti-infectives is utilizing digital platforms to reach healthcare professionals with state-of-art information shared by internationally recognized and trusted experts.

Holzkirchen, November 15, 2017 – Sandoz is holding today a Scientific Standalone Event “Combat …

/by

New data reinforces clinical basis for switching to Sandoz biosimilar medicines

  • Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab
  • Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively 
  • Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA

Holzkirchen, November 14, 2017– Sandoz, a Novartis division and the global leader in …

/by